Literature DB >> 26071600

Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary.

Robert A Byrne1, Patrick W Serruys2, Andreas Baumbach3, Javier Escaned4, Jean Fajadet5, Stefan James6, Michael Joner7, Semih Oktay8, Peter Jüni9, Adnan Kastrati1, George Sianos10, Giulio G Stefanini11, William Wijns12, Stephan Windecker13.   

Abstract

The evaluation for European Union market approval of coronary stents falls under the Medical Device Directive that was adopted in 1993. Specific requirements for the assessment of coronary stents are laid out in supplementary advisory documents. In response to a call by the European Commission to make recommendations for a revision of the advisory document on the evaluation of coronary stents (Appendix 1 of MEDDEV 2.7.1), the European Society of Cardiology (ESC) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) established a Task Force to develop an expert advisory report. As basis for its report, the ESC-EAPCI Task Force reviewed existing processes, established a comprehensive list of all coronary drug-eluting stents that have received a CE mark to date, and undertook a systematic review of the literature of all published randomized clinical trials evaluating clinical and angiographic outcomes of coronary artery stents between 2002 and 2013. Based on these data, the TF provided recommendations to inform a new regulatory process for coronary stents. The main recommendations of the task force include implementation of a standardized non-clinical assessment of stents and a novel clinical evaluation pathway for market approval. The two-stage clinical evaluation plan includes recommendation for an initial pre-market trial with objective performance criteria (OPC) benchmarking using invasive imaging follow-up leading to conditional CE-mark approval and a subsequent mandatory, large-scale randomized trial with clinical endpoint evaluation leading to unconditional CE-mark. The data analysis from the systematic review of the Task Force may provide a basis for determination of OPC for use in future studies. This paper represents an executive summary of the Task Force's report. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Keywords:  Bioresorbable stents; Coronary artery disease; Coronary stents; Drug-eluting stents; Percutaneous coronary interventions

Mesh:

Year:  2015        PMID: 26071600     DOI: 10.1093/eurheartj/ehv203

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  27 in total

Review 1.  Percutaneous coronary intervention: balloons, stents and scaffolds.

Authors:  Roisin Colleran; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2018-07-23       Impact factor: 5.460

2.  Safety and feasibility study of holmium laser enucleation of the prostate (HOLEP) on patients receiving dual antiplatelet therapy (DAPT).

Authors:  Jie Sun; An Shi; Zhen Tong; Wei Xue
Journal:  World J Urol       Date:  2017-11-14       Impact factor: 4.226

Review 3.  Is it time to take bare metal stents off the catheter laboratory shelf?

Authors:  George Kassimis; Adrian P Banning
Journal:  Eur Heart J       Date:  2016-06-09       Impact factor: 29.983

Review 4.  Bioresorbable vascular scaffolds - basic concepts and clinical outcome.

Authors:  Ciro Indolfi; Salvatore De Rosa; Antonio Colombo
Journal:  Nat Rev Cardiol       Date:  2016-09-29       Impact factor: 32.419

5.  Polymeric endovascular strut and lumen detection algorithm for intracoronary optical coherence tomography images.

Authors:  Junedh M Amrute; Lambros S Athanasiou; Farhad Rikhtegar; José M de la Torre Hernández; Tamara García Camarero; Elazer R Edelman
Journal:  J Biomed Opt       Date:  2018-03       Impact factor: 3.170

6.  Challenges in Patients with Diabetes: Improving Clinical Outcomes After Percutaneous Coronary Intervention Through EVOlving Stent Technology.

Authors:  Robert A Byrne; Shmuel Banai; Roisin Colleran; Antonio Colombo
Journal:  Interv Cardiol       Date:  2018-01

Review 7.  Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta-analysis.

Authors:  Eden Liu; Leon Hsueh; Hajwa Kim; Mladen I Vidovich
Journal:  Am Heart J       Date:  2017-09-08       Impact factor: 4.749

8.  Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis.

Authors:  Daniele Giacoppo; Roisin Colleran; Salvatore Cassese; Antonio H Frangieh; Jens Wiebe; Michael Joner; Heribert Schunkert; Adnan Kastrati; Robert A Byrne
Journal:  JAMA Cardiol       Date:  2017-10-01       Impact factor: 14.676

9.  PCI in Patients with Diabetes: Role of the Cre8 Drug-eluting Stent.

Authors:  Robert A Byrne; Eric Eeckhout; Gennaro Sardella; Pieter Stella; Stefan Verheye
Journal:  Interv Cardiol       Date:  2017-05

Review 10.  Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014.

Authors:  Robert A Byrne; Michael Joner; Adnan Kastrati
Journal:  Eur Heart J       Date:  2015-09-28       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.